Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Semaglutide belongs to the GLP-1 receptor agonist class, distinct from dual agonists such as tirzepatide
FDA-APPROVED INDICATIONS Injection Weight loss (adults) As an adjunct to diet and exercise for weight loss in adults with a BMI 30 or 27 in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes, dyslipidemia) [STEP 1 study] Adult BMI calculator Weight loss (children 12 years old) As an adjunct to a reduced-calorie diet and increased physical activity in pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex
Lower risk of desensitization: Alternating mechanisms prevent receptor fatigue or feedback inhibition
Safety depends on accurate medical screening, proper patient monitoring, and clear adverse event reporting
